About Eramol
Quality-led pharmaceutical manufacturing and supply, built by Qualified Persons
Eramol is a UK and EU-based pharmaceutical services company providing end-to-end manufacturing, packaging, quality and supply chain solutions for clinical and commercial medicinal products. Founded and led by Qualified Persons, Eramol was established with a clear purpose: to deliver compliant, reliable and flexible services with quality at the forefront of every decision.
Today, Eramol supports pharmaceutical and biotechnology companies across a wide range of modalities and development stages, offering integrated non-sterile and sterile manufacturing, packaging, Quality Control, QP release, storage and global distribution.
Founded by QPs, Built on Quality
Eramol was founded in 2013 by Peter Mollison and Eric Che, both experienced Qualified Persons, initially operating as virtual QPs supporting pharmaceutical companies with batch certification, regulatory oversight, and supply chain compliance.
This early experience working across multiple products, clients, and regulatory frameworks shaped Eramol’s DNA. From the outset, the business was designed around:
- Strong quality systems
- Practical regulatory understanding and support
- Client centric decision making
- Protecting product integrity and minimising drug losses
As client demand grew, Eramol evolved from virtual QP services into a fully integrated operational organisation with its own GMP and GDP facilities across the UK and EU.
ABOUT
Meeting your needs, today and in the future.
Eramol provides bespoke clinical trial solutions to meet a diverse array of its clients’ needs.
Evolving to meet market needs.
We are a responsive company and fully understand that requirements and needs change quickly in an ever-evolving environment. We do everything to address this fluidity, with an approach that constantly stays one step ahead of the market.
Founded by experts.
Eramol was co-founded by two Qualified Persons with significant experience in managing clinical trial manufacturing projects in both commercial and non-commercial organisations. Eric Che and Peter Mollison established Eramol together, building upon their expertise and industry knowledge, with the shared insight to provide a critical response to companies undertaking clinical trials.
Tailored Solutions
Customer Focused
Flexible Approach
Global Presence
Our History.
Eramol provides bespoke clinical trial solutions to meet a diverse array of its clients’ needs.
To explore more of the history, please drag the history view horizontally.
Our Growth Journey
Eramol’s expansion has been deliberate, capability-led, and driven by client needs:
- 2013 – Eramol founded by Peter Mollison and Eric Che as virtual QPs
- December 2017 – Acquisition of the Gatwick site (Eramol’s founding operational facility)
- April 2018 – Packaging, storage, and distribution services established
- December 2019 – Primary manufacturing introduced at Gatwick
- August 2020 – Dublin EU facility becomes operational
- November 2021 – Sevenoaks non-sterile site commissioned
- August 2022 – Sevenoaks non-sterile facility operational
- February 2023 – Home Office approval for Sevenoaks
- June 2023 – QC and stability expansion at Sevenoaks
- September 2023 – Acquisition of Sevenoaks sterile facility
- January 2024 – Sevenoaks warehouse expansion
- April 2024 – Sterile facility build initiated
- August 2024 – Labelling capability added at Dublin
- H1 2026 – Sevenoaks sterile facility operational
Each phase of growth has strengthened Eramol’s ability to offer true end-to-end services, reducing handovers, increasing control, and improving supply chain resilience for clients.
What We Do
Eramol provides fully integrated pharmaceutical services, including:
- Formulation Development
- Sterile Manufacturing
- Non Sterile Manufacturing
- Placebo Manufacturing
- Clinical Packaging
- Labelling Solutions
- EU & UK QP Release
- Clinical Storage & Distribution
- EU & UK Importation
- Commercial Drug Procurement
- Clinical Supply Chain Solutions
Our facilities and services are designed to work together, allowing clients to move seamlessly from development through to clinical and commercial supply.
Eramol provides fully integrated pharmaceutical services, including:
- Non-sterile manufacturing (solid oral dosage forms and oral liquids)
- Sterile manufacturing (aseptic and terminal sterilisation fill-finish)
- Packaging and labelling for clinical and commercial supply
- Quality Control (QC) testing and stability support
- QP release for the UK and EU
- GMP and GDP storage
- Global distribution
Our facilities and services are designed to work together, allowing clients to move seamlessly from development through to clinical and commercial supply.
Designed by QPs, for Modern Drug Development
Eramol’s facilities, particularly our Sevenoaks sterile and non-sterile siteshave been designed by Qualified Persons, ensuring regulatory compliance, inspection readiness, and patient safety are embedded from the ground up.
Key design principles include:
- Minimising product and API losses
- Reducing contamination and deviation risk
- Supporting complex and high-value therapies
- Enabling flexible batch sizes and rapid scale-up
- Ensuring data integrity and audit readiness
This QP-led approach allows Eramol to act not just as a service provider, but as a trusted partner in regulatory and supply strategy.
A Partner You Can Rely On
Eramol works with small and mid-sized biotech companies, virtual pharma organisations, academic institutions, CROs, and clinical trial units, as well as established pharmaceutical clients. We support programmes across early development through to commercial supply, tailoring our services to the needs of each partner and development stage.
Whether enabling first-in-human studies, supporting complex clinical trial supply chains, or preparing products for later-stage development and commercialisation, Eramol brings clarity, control, and confidence to complex manufacturing and regulatory environments.
Eramol — built on quality, driven by expertise, delivering end-to-end pharmaceutical solutions.
Company
The company is privately owned. As a private equity-free company, Eramol is able to act in the best interests of the Company and its Clients, with a focus on service, delivery and innovation.
People
Eramol was founded on the shared values of the co-founders to offer a tailored and responsive clinical trial manufacturing services to sponsors with a wide set of requirements.
Our Approach
Eramol has developed a profound customer process that aims to deliver complete satisfaction to our clients at every stage.
Accreditations
Eramol is an authorised organisation across many strategic areas of the business. Accreditations relate to MHRA, HPRA, MHRA GDP and WDA(v). We work with all relevant bodies to ensure the very latest accreditations are in line with ongoing, continuous developments in the industry.
Our History.
Eramol provides bespoke clinical trial solutions to meet a diverse array of its clients’ needs.
To explore more of the history, please drag the history view horizontally.